Literature DB >> 30123543

(J)ALEX the great: a new era in the world of ALK inhibitors.

Solenn Brosseau1,2, Valérie Gounant1, Gérard Zalcman1,2.   

Abstract

Entities:  

Year:  2018        PMID： 30123543      PMCID： PMC6072949          DOI： 10.21037/jtd.2018.06.142

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  25 in total

1.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Authors:  Alice T Shaw; Beow Y Yeap; Benjamin J Solomon; Gregory J Riely; Justin Gainor; Jeffrey A Engelman; Geoffrey I Shapiro; Daniel B Costa; Sai-Hong I Ou; Mohit Butaney; Ravi Salgia; Robert G Maki; Marileila Varella-Garcia; Robert C Doebele; Yung-Jue Bang; Kimary Kulig; Paulina Selaru; Yiyun Tang; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; A John Iafrate; D Ross Camidge
Journal:  Lancet Oncol       Date:  2011-09-18       Impact factor: 41.316

2.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Authors:  Shirish M Gadgeel; Leena Gandhi; Gregory J Riely; Alberto A Chiappori; Howard L West; Michele C Azada; Peter N Morcos; Ruey-Min Lee; Linta Garcia; Li Yu; Frederic Boisserie; Laura Di Laurenzio; Sophie Golding; Jotaro Sato; Shumpei Yokoyama; Tomohiro Tanaka; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2014-08-18       Impact factor: 41.316

3.  Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

Authors:  Aaron N Hata; Alice T Shaw; Satoshi Yoda; Jessica J Lin; Michael S Lawrence; Benjamin J Burke; Luc Friboulet; Adam Langenbucher; Leila Dardaei; Kylie Prutisto-Chang; Ibiayi Dagogo-Jack; Sergei Timofeevski; Harper Hubbeling; Justin F Gainor; Lorin A Ferris; Amanda K Riley; Krystina E Kattermann; Daria Timonina; Rebecca S Heist; A John Iafrate; Cyril H Benes; Jochen K Lennerz; Mari Mino-Kenudson; Jeffrey A Engelman; Ted W Johnson
Journal:  Cancer Discov       Date:  2018-04-12       Impact factor: 39.397

4.  Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Authors:  Robert C Doebele; Amanda B Pilling; Dara L Aisner; Tatiana G Kutateladze; Anh T Le; Andrew J Weickhardt; Kimi L Kondo; Derek J Linderman; Lynn E Heasley; Wilbur A Franklin; Marileila Varella-Garcia; D Ross Camidge
Journal:  Clin Cancer Res       Date:  2012-01-10       Impact factor: 12.531

5.  Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Shirish M Gadgeel; Alice T Shaw; Ramaswamy Govindan; Leena Gandhi; Mark A Socinski; D Ross Camidge; Luigi De Petris; Dong-Wan Kim; Alberto Chiappori; Denis L Moro-Sibilot; Michael Duruisseaux; Lucio Crino; Tommaso De Pas; Eric Dansin; Antje Tessmer; James Chih-Hsin Yang; Ji-Youn Han; Walter Bordogna; Sophie Golding; Ali Zeaiter; Sai-Hong Ignatius Ou
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

6.  Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.

Authors:  Alice T Shaw; Tae Min Kim; Lucio Crinò; Cesare Gridelli; Katsuyuki Kiura; Geoffrey Liu; Silvia Novello; Alessandra Bearz; Oliver Gautschi; Tony Mok; Makoto Nishio; Giorgio Scagliotti; David R Spigel; Stéphanie Deudon; Cheng Zheng; Serafino Pantano; Patrick Urban; Cristian Massacesi; Kalyanee Viraswami-Appanna; Enriqueta Felip
Journal:  Lancet Oncol       Date:  2017-06-09       Impact factor: 41.316

7.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316

8.  Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.

Authors:  Ryohei Katayama; Luc Friboulet; Sumie Koike; Elizabeth L Lockerman; Tahsin M Khan; Justin F Gainor; A John Iafrate; Kengo Takeuchi; Makoto Taiji; Yasushi Okuno; Naoya Fujita; Jeffrey A Engelman; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2014-09-16       Impact factor: 12.531

9.  Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Authors:  Alice T Shaw; Leena Gandhi; Shirish Gadgeel; Gregory J Riely; Jeremy Cetnar; Howard West; D Ross Camidge; Mark A Socinski; Alberto Chiappori; Tarek Mekhail; Bo H Chao; Hossein Borghaei; Kathryn A Gold; Ali Zeaiter; Walter Bordogna; Bogdana Balas; Oscar Puig; Volkmar Henschel; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2015-12-19       Impact factor: 41.316

10.  Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

Authors:  Alice T Shaw; Enriqueta Felip; Todd M Bauer; Benjamin Besse; Alejandro Navarro; Sophie Postel-Vinay; Justin F Gainor; Melissa Johnson; Jorg Dietrich; Leonard P James; Jill S Clancy; Joseph Chen; Jean-François Martini; Antonello Abbattista; Benjamin J Solomon
Journal:  Lancet Oncol       Date:  2017-10-23       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.